First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

749

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo
DRUG: Cisplatin
DRUG: 5-FU

Sponsor

Merck Sharp & Dohme LLC